文献速递浆细胞疾病

DKK1通过IL-6诱导的CKAP4受体激活非经典NF-κB信号促进多发性骨髓瘤耐药

DKK1 activates noncanonical NF-κB signaling via IL-6-induced CKAP4 receptor in multiple myeloma.
PubMed 文献 · Blood Adv · 2021-01-01

研究在多发性骨髓瘤(MM)中发现硼替佐米(BTZ)耐药细胞中DKK1水平显著升高而CD138显著降低。DKK1通过CKAP4受体激活NF-κB通路并诱导IL-6刺激CKAP4表达,形成耐药循环;干扰DKK1-CKAP4轴可改善BTZ敏感性并减轻小鼠模型骨破坏。

要点

  • BTZ耐药MM细胞中DKK1升高、CD138降低,DKK1增强BTZ耐药。
  • DKK1经CKAP4受体激活非经典NF-κB信号并诱导IL-6上调CKAP4。
  • 干扰DKK1-CKAP4轴可改善BTZ敏感性并减轻小鼠骨破坏。

核心结论

  • DKK1通过Wnt依赖和非依赖方式促进骨髓瘤耐药,拮抗DKK1-IL-6环路具潜在治疗价值。

研究设计与样本

  • 在硼替佐米耐药MM细胞中筛选差异表达细胞因子,并行体外及小鼠模型验证。

主要发现

  • BTZ耐药MM细胞中DKK1水平显著升高,CD138水平显著降低。
  • DKK1体外特异性增强骨髓瘤细胞对BTZ的耐药性。
  • 过量DKK1通过抑制经典Wnt信号下调CD138。
  • DKK1主要经CKAP4受体诱导MM细胞耐药。
  • CKAP4招募并阻止CAND1妨碍E3连接酶介导的IκBα泛素化组装,从而激活NF-κB通路。

临床怎么用

  • DKK1-CKAP4轴及IL-6环路可作为克服BTZ耐药和骨破坏的潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proteasome inhibitors, such as bortezomib (BTZ), represent the key elements in chemotherapy regimens for multiple myeloma (MM), whereas acquired chemoresistance and ultimately relapse remain a major obstacle. In the current study, we screened differently expressed cytokines in bortezomib-resistant MM cells and found that Dickkopf-1 (DKK1) level was remarkably augmented, whereas CD138 level was significantly suppressed. DKK1 in vitro specifically enhanced the resistance of myeloma cells to bortezomib treatment, and excessive DKK1 drove CD138 downregulation via inhibition of canonical Wnt signaling. Notably, DKK1 mainly induced drug resistance in MM cells via the receptor of CKAP4. Mechanistically, CKAP4 transduced DKK1 signal and evoked NF-κB pathway through recruiting and preventing cullin associated and neddylation dissociated 1 from hampering the assembly of E3 ligase-mediated ubiquitination of IκBα. In addition, we found that interleukin-6 (IL-6) stimulated CKAP4 expression to generate drug resistance, and disturbance of DKK1-CKAP4 axis improved sensitivity to BTZ treatment of MM and attenuated bone destruction in a mouse model. Collectively, our study revealed the previously unidentified role of DKK1 in myeloma drug resistance via Wnt signaling dependent and independent manners, and clarified the importance of antagonism of DKK1-IL-6 loop in bone marrow microenvironment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li X, Wang J, Zhu S, et al. DKK1 activates noncanonical NF-κB signaling via IL-6-induced CKAP4 receptor in multiple myeloma. Blood Adv. 2021. PMID: 34470047. doi:10.1182/bloodadvances.2021004315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。